Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $2.50.

Several research analysts recently commented on the company. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Tuesday, September 19th. Roth Capital set a $2.00 price target on Ritter Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, HC Wainwright dropped their price target on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research report on Monday, October 23rd.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Susquehanna International Group LLP purchased a new stake in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned approximately 4.49% of Ritter Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 33.38% of the stock is currently owned by institutional investors and hedge funds.

Ritter Pharmaceuticals (RTTR) traded up $0.01 during trading hours on Thursday, reaching $0.29. The company’s stock had a trading volume of 392,863 shares, compared to its average volume of 587,721. Ritter Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.14). equities research analysts predict that Ritter Pharmaceuticals will post -0.66 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/14/ritter-pharmaceuticals-inc-rttr-given-average-recommendation-of-buy-by-analysts.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.